PDCD1 and Hodgkins lymphoma: Currently, only Hodgkin’s lymphoma (HL) and primary mediastinal B-cell lymphoma (PMBL) [26] have received EMA and/or FDA approval for two anti-PD1 monoclonal antibodies: nivolumab (Nivo) and pembrolizumab (Pembro).